SCHEMBL6824874

SCHEMBL6824874

c1ccc2nc(-c3cc4ccccc4o3)c(-c3ncc[nH]3)cc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA2A P08913 4/20 0.68
▸ ADRA2B P18089 3/20 0.47
▸ ADRA2C P18825 3/20 0.47
▸ NPC1 O15118 4/20 0.42
▸ RAB9A P51151 4/20 0.42
▸ ALDH1A1 P00352 4/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ MAOA P21397 2/20 0.40
▸ MAOB P27338 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ NISCH Q9Y2I1 2/20 0.40
▸ GRM4 Q14833 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ METAP2 P50579 1/20 0.38
▸ CYP19A1 P11511 1/20 0.38
▸ MAPT P10636 3/20 0.37
▸ KDM5A P29375 1/20 0.37
▸ KDM4C Q9H3R0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30979447 0.82 ADRA2A (0.46) ADRA2AADRA2BADRA2CNPC1RAB9A
SCHEMBL563350 0.82 ADRA2A (1.00) ADRA2AADRA2BADRA2CNPC1RAB9A
Hydrochloric Acid SCHEMBL9295322 0.81 ADRA2A (0.97) ADRA2AADRA2BADRA2CNPC1RAB9A
Hydrochloric Acid SCHEMBL30865655 0.81 ADRA2A (0.97) ADRA2AADRA2BADRA2CNPC1RAB9A
SCHEMBL6824177 0.78 MTOR (0.54) ADRA2ANPC1RAB9AALDH1A1KDM4E
SCHEMBL7660143 0.70 NPC1 (0.44) ADRA2ANPC1RAB9AALDH1A1KDM4E
SCHEMBL2563442 0.69 ADRA2A (0.42) ADRA2AADRA2BADRA2CNPC1RAB9A
SCHEMBL39553 0.68 ALDH1A1 (0.47) ADRA2AADRA2BADRA2CNPC1RAB9A
SCHEMBL4329170 0.68 ADRA2A (0.50) ADRA2AADRA2BADRA2CALDH1A1KDM4E
SCHEMBL10009278 0.67 KDM4E (0.49) ADRA2AADRA2BADRA2CNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 — — US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 — — EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 — — EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 — — US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 — — WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R ADRA2A 1004/4885ADRA2B 964/4885ADRA2C 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback